DavidM.GershensonMD

Obstetrics & Gynecology • Houston, TX

General Gynecology, Gynecologic Oncology

Professor of Obstetrics & Gynecology, University Tex Houston

Join to view full profile

Dr. Gershenson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gershenson's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 1977 - 1979
Yale-New Haven Medical CenterResidency, Obstetrics and Gynecology, 1972 - 1975
University of Iowa Hospitals and ClinicsInternship, Transitional Year, 1971 - 1972
Vanderbilt University School of MedicineClass of 1971

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TX State Medical License 1979 - 2025
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer Start of enrollment: 1997 Dec 08
Completed
Not Applicable
Research Study in Patients With Advanced Ovarian Epithelial Cancer Start of enrollment: 2002 Nov 01
Withdrawn
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors Start of enrollment: 2006 May 19
Recruiting
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Start of enrollment: 2003 Dec 29
Terminated
Phase 1, Phase 2
Gleevec Study for Patients With Ovarian Cancer Start of enrollment: 2002 Mar 01
Completed
Phase 2
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Start of enrollment: 2007 Dec 17
Completed
Phase 2
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary Start of enrollment: 2008 Sep 22
Completed
Phase 2
Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2002 Feb 01
Terminated
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
Active, not recruiting
Phase 3
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Start of enrollment: 2014 Feb 27
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Survival outcomes comparing minimally invasive versus open cytoreductive surgery in recurrent adult-type granulosa cell tumors.
Allison L Brodsky, Alejandra Flores Legarreta, Jeffrey A How, Veena Vuttaradhi, Anil K Sood
American Journal of Obstetrics and Gynecology. 2025-01-15
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients w...
Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, Kathleen Nadine Moore, Michel Fabbro
International Journal of Gynecological Cancer. 2025-01-06
1 citations
promoter mutations and survival outcomes in adult-type granulosa cell tumors.
Allison L Brodsky, Alejandra Flores Legarreta, Bryan M Fellman, Deanna Glassman, Jeffrey How
International Journal of Gynecological Cancer. 2025-01-06

Journal Articles

KMT2D/MLL2 Inactivation Is Associated with Recurrence in Adult-Type Granulosa Cell Tumors of the Ovary
R Tyler Hillman, Karen H Lu, David M Gershenson, Nature

Lectures

Scientific and Clinical Update in Gynecologic Oncology
Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania - 5/3/2013

Other

Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis
Gershenson DM
http://www.uptodate.com/contents/ovarian-germ-cell-neoplasms-pathology-clinical-manifestations-and-d
UpToDate, Wolters Kluwer Health - 2012-08-08
Overview of sex cord-stromal tumors of the ovary
Gershenson DM
http://www.uptodate.com/contents/overview-of-sex-cord-stromal-tumors-of-the-ovary
UpToDate, Wolters Kluwer Health - 2012-08-28
Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors
Gershenson DM
http://www.uptodate.com/contents/sex-cord-stromal-tumors-of-the-ovary-granulosa-stromal-cell-tumors
UpToDate, Wolters Kluwer Health - 2012-12-17
Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors
Gershenson DM
http://www.uptodate.com/contents/sex-cord-stromal-tumors-of-the-ovary-sertoli-stromal-cell-tumors
UpToDate, Wolters Kluwer Health - 2013-01-30
Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements
Gershenson DM
http://www.uptodate.com/contents/sex-cord-stromal-tumors-of-the-ovary-tumors-with-granulosa-and-sert
UpToDate, Wolters Kluwer Health - 2013-03-29
Join now to see all

Press Mentions

Trametinib Is a New Treatment Option for Rare Form of Ovarian CancerMarch 10th, 2022
Trametinib Slows Recurrent Low-Grade Serous Ovarian CarcinomaFebruary 10th, 2022
Trametinib: New Go-to for Low-Grade Serous Ovarian Carcinoma?February 10th, 2022
Join now to see all

Grant Support

P3 - Personalized Therapy For Low-Grade Serous Carcinoma Of The OvaryNational Cancer Institute2010–2011
Developmental Research ProgramNational Cancer Institute2010–2011
Career Developmental ProgramNational Cancer Institute2010–2011
Administrative CoreNational Cancer Institute2008–2011
Training Of Academic Gynecologic OncologistsNational Cancer Institute2005–2009